VivoSeq
Other

PARP Inhibitor

0

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

PARP Inhibitor is an early-stage landscape with 0 programs across 3 companies. The most active players are AstraZeneca, Pfizer, Tango Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

63/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalT

Tango Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed5 · 42%
Recruiting3 · 25%
Withdrawn2 · 17%
Not yet recruiting1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

12 trials

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Recruiting·FFundación de investigación HM·Phase 2·NCT06607692·25 enrolled
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
Recruiting·EErasmus Medical Center·Phase 1·NCT05870423·24 enrolled
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT05053854·24 enrolled
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Not yet recruiting·YYonsei University·Phase 2·NCT07340164·116 enrolled
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00516724·189 enrolled
Pancytopenia Related to PARP Inhibitors (PancytoRIB)
Completed·UUniversity Hospital, Caen·N/A·NCT04774627·200 enrolled
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
Completed·Pfizer logoPfizer·Phase 1·NCT01776437·18 enrolled
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00516438·48 enrolled
Basket Trial of IDX-1197, a PARP Inhibitor, in Patients with HRR Mutated Solid Tumors (VASTUS)
Completed·IIdience Co., Ltd.·Phase 1/2·NCT04174716·108 enrolled
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Terminated·TTango Therapeutics, Inc.·Phase 1/2·NCT06065059·7 enrolled
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Withdrawn·YYale University·Phase 1·NCT02686008
Response to PARP Inhibitor Predicted by the RAD51 Assay
Withdrawn·UUniversity Medical Center Groningen·Phase 2·NCT03044795

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)